Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(14%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_4
2
29%
Ph phase_1
3
43%
Ph phase_3
1
14%
Ph phase_2
1
14%

Phase Distribution

3

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 21 (14.3%)
Phase 31 (14.3%)
Phase 42 (28.6%)

Trials by Status

completed457%
unknown114%
recruiting114%
withdrawn114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

NCT06680128
completedphase_1

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
unknownphase_2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

NCT05568953
completedphase_4

Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine

NCT01398540
completedphase_3

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

NCT01296360
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06680128Phase 1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Recruiting
NCT02963909Phase 1

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Completed
NCT05568953Phase 2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Unknown
NCT01398540Phase 4

Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine

Completed
NCT01296360Phase 3

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

Completed
NCT01559831Phase 1

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Withdrawn
NCT01158599Phase 4

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7